Synthesis of silver nanoparticles and hybridization with Bovine serum albumin nanoparticles as a nanocarrier for quercetin and investigation of its anticancer effects on ۴T۱ cell line
محل انتشار: پنجمین کنگره بین المللی سرطان
سال انتشار: 1400
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 335
نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
CANCERMED05_156
تاریخ نمایه سازی: 27 دی 1400
چکیده مقاله:
Introduction:In women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death. The anti-cancer effects of quercetin (Que) such as cellular signaling, apoptosis, anti-proliferation, anti-oxidant and growth suppression have been reported by several studies. On the other hand, treatment with anti-cancer nanodrugs causes the drug to accumulate in tumor tissue, minimizing drug interactions in off-target tissue, ameliorating direct effects, and inhibiting indirect effects and side effects. Silver nanoparticles have attracted a considerable interest in the field of cancer research due to their potential utility in cancer therapy.Materials and Methods:In the present study, we developed Ag NPs hybrid with BSA Nps (Ag@BSA NPs) and characterized in vitro therapeutic activities of this NPs for the treatment of breast cancer. Ag@BSA NPs were synthesized by a single-step reduction process, and the successful preparation was verified through a list of physical characterizations, including SEM, EDX, UV spectroscopy and DLS. These Ag@BSA@QUE NPs also demonstrated sustained release of QUE at ۳۷ °C in different buffer solutions.Results:The Ag@BSA@QUE NPs showed significant anti-cancer effects on ۴T۱ cells. These NPs decreased cell proliferation as well as increased apoptosis, which may have been caused by oxidative stress.Conclusion:It can be concluded that Ag@BSA@QUE NPs could potentially suppress the cancerous properties of ۴T۱ cells and the presented nanocarrier system can be a promising approach for targeted drug delivery in cancer treatment.
کلیدواژه ها:
نویسندگان
Mahmud Gharbavi
Zanjan Pharmaceutical Biotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
Ali Sharafi
Zanjan Pharmaceutical Biotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
Roghayeh Ghorbani
Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
Behrooz Johari
Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran